Metallo-β-lactamases
(MBLs) can efficiently catalyze the
hydrolysis of all classes of β-lactam antibiotics except monobactams.
While serine-β-lactamase (SBL) inhibitors (e.g., clavulanic
acid, avibactam) are established for clinical use, no such MBL inhibitors
are available. We report on the synthesis and mechanism of inhibition
of
N
-sulfamoylpyrrole-2-carboxylates (NSPCs) which
are potent inhibitors of clinically relevant B1 subclass MBLs, including
NDM-1. Crystallography reveals that the
N
-sulfamoyl
NH
2
group displaces the dizinc bridging hydroxide/water
of the B1 MBLs. Comparison of crystal structures of an NSPC and taniborbactam
(VRNX-5133), presently in Phase III clinical trials, shows similar
binding modes for the NSPC and the cyclic boronate ring systems. The
presence of an NSPC restores meropenem efficacy in clinically derived
E. coli
and
K. pneumoniae bla
NDM-1. The
results support the potential of NSPCs and related compounds as efficient
MBL inhibitors, though further optimization is required for their
clinical development.